66th ASH Annual Meeting: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma

Symposia: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms Oral and Poster Abstracts
Oral

Research, Fundamental Science, Apoptosis, Translational Research, Lymphomas, Drug development, Bispecific Antibody Therapy, Non-Hodgkin lymphoma, B Cell lymphoma, Diseases, Indolent lymphoma, Aggressive lymphoma, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Non-Biological therapies, Biological Processes, Pharmacology, Molecular biology, Technology and Procedures, Study Population, Pathogenesis, Animal model, Omics technologies

Ballroom 20CD (San Diego Convention Center)

Moderators:

Piers Blombery, MBBS, Peter Maccallum Cancer Centre and Daniel Herranz, PharmD, PhD, The Cancer Institute of New Jersey

Disclosures:

No relevant conflicts of interest to declare.

4:30 PM

955

Deciphering the Mechanism of Action of the Novel Celmod, Golcadomide, during Germinal Center B Cell Immune Response and in a Preclinical Mouse Model of Follicular Lymphoma

Caroline Huber¹^*, Yumi Nakayama, PhD²^*, Camille Soun¹^*, Noushin Mossadegh-Keller, PhD¹^*, Sophie Guia, PhD¹^*, Melanie Collin¹^*, Alexandre Sarrabay¹^*, Lionel Chasson¹^*, Lionel Spinelli, PhD¹^*, Bertrand Nadel, PhD^3,4, Anita K. Gandhi, PhD⁵, Gabriel Brisou, MD, PhD^1,6^*, Patrick R. Hagner, PhD²^* and Sandrine Roulland, PharmD, PhD¹^*

¹Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France
²Bristol Myers Squibb, Summit, NJ
³Institut Carnot Calym, Lyon, France
⁴Centre D'Immunologie De Marseille-Luminy, Marseilles, France
⁵Hematology, Translational Medicine, Bristol Myers Squibb, Summit, NJ
⁶Institut Paoli-Calmettes, Marseille, France

4:45 PM

956

A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells

Ran Kong¹^*, Shi Feng²^*, Cong Wang³^*, Qingbo Hao²^*, Yu Zhang⁴^*, Jingjing Han⁵^*, Xiaoyu Xie²^*, Haiyang Wang²^*, Jan Elsner⁶^*, Derek Mendy⁶^*, Michael Haughey⁶^*, Paul Krenitsky⁶^*, Veronique Plantevin-Krenitsky⁶^*, Patrick Papa⁶^*, Frank Mercurio⁶^*, Weilin Xie⁶^* and Xiangxiang Zhou, MD⁴

¹Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
²Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
³Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, AL, China
⁴Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
⁵Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
⁶Innovo Therapeutics, San Diego

5:00 PM

957

BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin’s Lymphoma

Lynda Groocock¹^*, Gauri Deb¹^*, Jinyi Zhu¹^*, Jim Gamez¹^*, Paola Castiglioni¹^*, Manuel Sanchez-Castillo²^*, Justin Schumacher³^*, Alicia Benitez Rondan²^*, Diana Jankeel¹^*, Karla Martinez-Garcia¹^*, Scott Wood¹^*, Andy Christoforou¹^*, Carla Guarinos²^*, Wei Zhang¹^*, Rama Krishna Narla¹^*, Christoph W. Zapf¹^*, Soraya Carrancio, PhD¹^*, Daniel W. Pierce⁴^*, Mark Rolfe¹, Neil Bence¹^*, Antonia Lopez-Girona¹^* and Deborah S. Mortensen¹^*

¹Research and Development, Bristol Myers Squibb, San Diego, CA
²Center for Innovation and Translational Research Europe (CITRE), Bristol Myers Squibb, Seville, Spain
³Research and Development, Bristol Myers Squibb, New Brunswick, NJ
⁴Research and Development, Bristol Myers Squibb, Brisbane, CA

5:15 PM

958

KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity

Wenzhuo Zhuang¹^*, Yuchen Zhang²^*, Chunxiao Yang³^*, Linlin Qin¹^*, Ruijing Hu¹^*, Menglu Chen²^*, Xinyuan Zhang²^*, Qi Li²^*, Xingping Lang³^*, Si Chen³^* and Bingzong Li, MD, PhD⁴

¹Suzhou Medical College of Soochow University, Suzhou, China
²The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
³Suzhou Sano Precision Medicine Ltd, Suzhou, China
⁴Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

5:30 PM

959

Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager, for B-Non Hodgkin Lymphoma Indications

Rachel Lawrence¹^*, Corinne Cayatte, PhD²^*, Macarena Izuzquiza Fernandez³^*, Scott Rata⁴^*, Thomas Ciucci²^*, Wen Lin²^*, Abigail Lara²^*, Nazli Jafarzadeh²^*, Taylor Foreman²^*, Sterling Payne⁵^*, Harini Shandilya⁵^*, Nisha Sambamurthy⁶^*, Haibin Luo⁷^*, Richard Stebbings¹^*, Simon Dovedi⁸^*, Gullu Gorgun⁹^*, Anthony Mato¹⁰^*, Saso Cemerski²^*, Mark Cobbold¹¹^* and Anas Younes¹⁰

¹Safety Sciences, AstraZeneca, Early Oncology R&D, Cambridge, United Kingdom
²Immune Engagers, AstraZeneca, Early Oncology R&D, Gaithersburg, MD
³Clinical, AstraZeneca, Hematology R&D, Barcelona, Spain
⁴Translational DMPK, AstraZeneca, Early Oncology R&D, Waltham, MA
⁵Biologics Engineering, AstraZeneca, Early Oncology R&D, Gaithersburg, MD
⁶Translational Medicine, AstraZeneca, Hematology R&D, South San Francisco, CA
⁷Biopharmaceutical Development, BioPharmaceutical R&D, Gaithersburg, MD
⁸Immune Engagers, AstraZeneca, Early Oncology R&D, Cambridge, United Kingdom
⁹AstraZeneca Hematology R&D, Waltham, MA
¹⁰AstraZeneca Hematology R&D, New York, NY
¹¹Immune Engagers, AstraZeneca, Early Oncology R&D, Waltham, MA

5:45 PM

960

CD93⁺ Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity

Hui Yu¹^*, Yixin Qian²^*, Weiping Liu³^*, Lan Mi⁴^*, Yun Huang⁵^*, Rui Peng⁶^*, Jiaowu Cao⁵^*, Dingyao Hu⁵^*, Jun Zhu, PhD⁷, Yuqin Song, MD⁸ and Mi Deng, PhD⁹^*

¹Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China
²Peking university basic medical school, Beijing, China
³Peking University Cancer Hospital, Beijing, China
⁴Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
⁵Beijing Cancer Hospital, Beijing, China
⁶Peking University School of Basic Medical Science, Beijing, China
⁷Department of Lymphoma, Peking University Cancer Hospital, Beijing, Beijing, China
⁸Department of Lymphoma, Peking University Cancer Hospital, BEIJING, China
⁹State Key Laboratory of Molecular Oncology, Beijing Key Laboratory of Carcinogenesis and Translational Research, Deng Mi Lab, Peking University Cancer Hospital & Institute, Beijing, Beijing, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

605.O2.6 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma